1. Home
  2. RGEN vs HALO Comparison

RGEN vs HALO Comparison

Compare RGEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$162.51

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$67.12

Market Cap

7.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGEN
HALO
Founded
1981
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2B
7.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGEN
HALO
Price
$162.51
$67.12
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$174.90
$73.33
AVG Volume (30 Days)
701.7K
2.6M
Earning Date
10-28-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.68
EPS
0.03
4.74
Revenue
$707,890,000.00
$1,242,852,000.00
Revenue This Year
$17.84
$34.83
Revenue Next Year
$12.57
$24.84
P/E Ratio
$5,259.20
$14.22
Revenue Growth
11.74
31.19
52 Week Low
$102.97
$46.26
52 Week High
$182.52
$79.50

Technical Indicators

Market Signals
Indicator
RGEN
HALO
Relative Strength Index (RSI) 54.15 54.13
Support Level $156.01 $61.23
Resistance Level $165.02 $66.60
Average True Range (ATR) 4.65 2.03
MACD -1.07 0.28
Stochastic Oscillator 43.33 81.90

Price Performance

Historical Comparison
RGEN
HALO

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: